Memorial Sloan Kettering Cancer Center Psychopharmacology in Cancer Care 2024 Memorial Sloan Kettering Include: 11 videos + 14 pdfs, size: 7.93 GB Target Audience: Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians Sample video: contact me for sample video Information: Date & Location Saturday, April 6, 2024, 8:30 AM – 5:30 PM, Online, New York, NYSpecialties Specialties – Behavioral Care, Critical Care, General and Family Practice, Geriatric Medicine, Hematology, Integrative Medicine, Internal Medicine, Medical Oncology, Neurology, Nurse Anesthetist, Nurse Practitioner, Nursing, Pain Medicine, Psychiatry, Psychology, Social Work Overview Clinicians have numerous tools at their disposal to help adult cancer patients deal with symptoms of depression, anxiety, and other cancer sequelae. Psychiatric medications are most frequently prescribed to cancer patients by oncologists and general practitioners, however, psychiatric syndromes are often underdiagnosed and undertreated. Few oncology practices have dedicated psychiatric consultants familiar with the nuances of Psycho-Oncology.Even when patients receive psychotropic medications appropriately, they may have problems that arise before their next oncology visit or before they see the person who prescribed their psychiatric medications. Psychologists, nurses, and social workers play an essential role in identifying psychological and physical symptoms as well as both beneficial and problematic medication effects as they provide frontline psychosocial interventions and support for cancer patients.This course is designed for the non-prescribing psycho-oncology clinician as well as the psychiatrist who is new to the world of Psycho-pharmaco-oncology. Oncologists, palliative care clinicians, advanced practice nurses, and oncology nurses will find this course useful as well. Expert faculty will focus on key target disorders and symptoms amenable to psychopharmacological intervention, including anxiety, depression, delirium, sleep disturbance, pain, fatigue, and weight and appetite loss.The course will also include updates on COVID-19-related delirium and the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain. The role of clinical social work in psychosocial support will also be reviewed. Participants will learn to identify psychological reactions to medical conditions or treatments; psychiatric presentations of medical conditions or treatments; medical presentations of psychiatric conditions and common medical complications of psychiatric conditions or treatments.Basic information will be presented about medications used to alleviate Quality of Life symptoms that arise in the cancer setting from diagnosis to survivorship or end-of-life care, and the interface of psychotherapy and medication management. We will review why certain medications are used and why some are avoided, looking at potential benefits, unwanted side effects, and drug-drug interactions, since you may be the first person to identify a serious adverse event. The course will also enhance your ability to provide psychoeducation to patients regarding psychiatric medications.This educational program is co-sponsored by the MSK Psycho-Oncology Education and Training Institute (POETI).Who Should AttendThe target audience for this course includes Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians, Physician Assistants, Nurse Practitioners, Nurses, Psychologists, Social Workers and CounselorsObjectives Describe basic psycho-pharmaco-oncology principles for understanding and treating anxiety, depression and delirium in people with cancer. Discuss basic psycho-pharmaco-oncology principles for understanding and improving quality of life and psychiatric palliative care in people with cancer, including managing cognitive changes, insomnia, fatigue, poor appetite and weight loss, and pain. Identify the nuances of psycho-pharmaco-oncology related to COVID-19 related delirium and the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain in people with cancer. Topics: Anxiety Disorders.mp4 Anxiety Disorders.pdf Cancer and Cancer-Treatment Related Cognitive Changes.mp4 Cancer and Cancer-Treatment Related Cognitive Changes.pdf Cancer-Related Fatigue.mp4 Cancer-Related Fatigue.pdf Caring for the Whole Patient- The Role of Clinical Social Work in Psychosocial Support.mp4 Caring for the Whole Patient- The Role of Clinical Social Work in Psychosocial Support.pdf Delirium Handouts.pdf Delirium.mp4 Delirium.pdf Depressive Disorders.mp4 Depressive Disorders.pdf Fatigue Handouts.pdf Ketamine and Esketamine for Depression.mp4 Ketamine and Esketamine for Depression.pdf Novel Psychopharmacologic Interventions in Oncology.mp4 Novel Psychopharmacologic Interventions in Oncology.pdf Pain.mp4 Psychopharm2024_Brochure.pdf Sleep Disorders.mp4 Sleep Disorders.pdf Sleep Handout.pdf Weight and Appetite Loss.mp4 Weight and Appetite Loss.pdf
Related
Related
Related
Related